In Nice, an Inserm team has developed a molecule that could well revolutionize the treatment of this cancer.
Le reindeer cancer is linked to a mortality rate because if there are treatments to slow it down, it is now incurable.
But the outlook is much more optimistic since the development of a new molecule by Dr. Gilles Pagès, research director at Inserm and team leader at the Cancer and Aging Institute (Ircan) in Nice, along with other researchers.
Fifteen years of research
When he started working on the subject 15 years ago, he recalls that life expectancy was then 3 months on average: “Little by little, we managed to reach an average of three years. We gained years and quality of life”. And this, thanks to the arrival of many new treatments.
This molecule, associated with other treatments already available, is likely to lengthen the life of patients. At 20Minutes, he summarizes: “Our treatment, combined with those that already exist, will hopefully make this disease curable. But just to be able to make it a chronic disease and allow patients to live, it is an immense pride”.
In addition, this molecule “is also effective for tumor models insensitive to immunotherapy”, adds the specialist who received the prize from the Amgen France fund for Science and Humans on Friday May 6th.
A first clinical test in 2023
So, when will a treatment for metastatic cancer be available? You have to be patient. Dr Pagès says: “We are currently in the regulatory toxicology phases, which will be finalized by the end of 2022, or even the beginning of 2023. Then, we must submit the treatment to the health authorities of the European Medicines Agency, with a first ongoing clinical trial. 2023”.
To save time, a start-up was founded in April 2021, which “has collected all possible prizes and funding from the academy and is even a winner of the i-Lab”.
Beyond kidney cancer alone, his work could also promote the emergence of solutions for patients suffering from other cancers, such as “uveal melanoma” or “cancers of the ENT sphere”.
👏 Proud to have presented ajd to the @Lacassagne_Nice the Fund Price @AmgenFrance for Science and the Human to Dr. @PagsGilles1 @Inserm @ircaninstitute for his project Optimizing the Treatment of Kidney Cancer
Especially in the presence of #NathalieVaroqueaux @AmgenFrance #PrPaulHofman pic.twitter.com/PpefE57UL2
— BARRANGER Emmanuel (@Emm_BARRANGER) May 6, 2022